Recent studies with anti-CD19 CAR T cells in ALL patients have suggested that blood-brain barrier (BBB) disruption following activation of vascular endothelium might play a major role in ICANS (96, 97). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.